Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CBUS
CBUS logo

CBUS Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
2.010
Open
1.950
VWAP
1.96
Vol
306.76K
Mkt Cap
138.63M
Low
1.890
Amount
600.22K
EV/EBITDA(TTM)
--
Total Shares
76.17M
EV
364.16M
EV/OCF(TTM)
--
P/S(TTM)
22.86
Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.
Show More

Events Timeline

(ET)
2026-03-26
07:50:00
BTIG Acts as Sole Underwriter for the Offering
select
2026-03-25 (ET)
2026-03-25
16:10:00
Cibus Plans Public Offering of Class A Common Stock
select
2026-03-18 (ET)
2026-03-18
09:00:00
U.S. Stock Futures Lower as Investors Weigh Oil Prices Against Geopolitical Risks
select
2026-03-17 (ET)
2026-03-17
19:40:00
Stock Futures Slightly Lower Amid Oil Price Volatility
select
2026-03-17
16:20:00
Cibus Q4 Revenue $1.06M, Below Consensus
select
2026-02-06 (ET)
2026-02-06
07:20:00
Cibus Joins UK Agriculture Innovation Project
select
2026-01-29 (ET)
2026-01-29
07:30:00
Cibus Prices Public Offering of 13.33 Million Shares at $1.50 Each
select

News

seekingalpha
8.5
03-26seekingalpha
Cibus Shares Drop Over 20% After Pricing Public Offering
  • Offering Pricing: Cibus priced its public offering at $2.15 per share for 6,976,744 shares, resulting in a premarket drop of over 20%, indicating negative market sentiment towards the financing plan.
  • Underwriter Option: The company granted the underwriter a 30-day option to purchase up to 1,046,511 shares of Class A Common Stock to cover over-allotments, which could further dilute existing shareholders' stakes.
  • Clear Use of Proceeds: The offering is expected to raise approximately $15 million (or $17.2 million if the underwriter fully exercises the option), with net proceeds intended for working capital and general corporate purposes, particularly to fund the development of weed management traits in rice.
  • Closing Timeline: The public offering is expected to close on March 27, 2026, and the company's funding strategy will directly impact its R&D progress and competitive positioning in the agricultural technology sector.
Yahoo Finance
8.5
03-26Yahoo Finance
Cibus Inc. Prices Public Offering of Class A Common Stock
  • Offering Size: Cibus Inc. has priced its public offering at $2.15 per share for 6,976,744 shares of Class A Common Stock, aiming to raise approximately $15 million, with potential total proceeds of $17.2 million if the underwriter fully exercises its over-allotment option, indicating strong market demand for the company's shares.
  • Use of Proceeds: The net proceeds from the offering are intended for working capital and general corporate purposes, particularly to fund the further development of its weed management traits in rice, which aims to enhance product competitiveness and meet market demands.
  • Underwriter Selection: BTIG, LLC is acting as the sole underwriter for the offering, reflecting the company's professionalism and market credibility in choosing partners, which is expected to facilitate the smooth execution of the offering.
  • Compliance and Transparency: The offering is being conducted under an effective shelf registration statement on Form S-3, ensuring compliance and transparency, which enhances investor confidence in Cibus and supports the company's ongoing growth in the agricultural technology sector.
seekingalpha
8.5
03-25seekingalpha
Cibus Announces Public Offering of Class A Common Stock
  • Public Offering Announcement: Cibus has announced its intention to offer shares of Class A common stock and pre-funded warrants, reflecting the company's proactive approach to capital markets aimed at enhancing financial flexibility for future growth.
  • Underwriting Arrangement: BTIG, LLC is acting as the sole underwriter for the offering, indicating professional support in capital markets that is expected to boost investor confidence and facilitate market acceptance of the stock.
  • Additional Purchase Option: Cibus expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the Class A common stock, further enhancing the offering's flexibility and market appeal, potentially bringing in additional funding for the company.
  • Use of Proceeds: The net proceeds from the offering will be used for working capital and general corporate purposes, including further development of weed management traits in rice, demonstrating the company's ongoing investment and strategic focus in the agricultural biotechnology sector.
NASDAQ.COM
9.5
03-19NASDAQ.COM
Cibus Reports Q4 2025 Financial Results and Future Milestones
  • Widening Financial Loss: Cibus reported a net loss of $31.9 million for Q4 2025, up from $25.8 million the previous year, indicating financial strain that may impact future funding capabilities.
  • Cash Flow Status: As of December 31, 2025, Cibus had $9.9 million in cash and cash equivalents, expected to fund operations and capital expenditures into late Q3 2026, reflecting tight liquidity.
  • Market Expansion Plans: Cibus aims to establish new customer relationships with rice seed companies across the US, LATAM, and India in 2026, highlighting its focus on global market opportunities and growth potential.
  • Technological Innovation: The proprietary Cibus Trait Machine, based on its patented Rapid Trait Development System (RTDS), represents a technological breakthrough in plant breeding, expected to enhance the company's competitiveness in precision breeding.
Yahoo Finance
9.5
03-18Yahoo Finance
Cibus Inc. Reports Q4 2025 Financial Results and Strategic Developments
  • Financial Overview: As of December 31, 2025, Cibus Inc. reported cash and cash equivalents of $9.9 million, indicating financial management pressures, particularly with a net loss of $31.9 million in Q4, up from $25.8 million the previous year, reflecting ongoing operational challenges.
  • R&D and Operating Cost Control: The company achieved approximately $10 million in reductions across R&D and SG&A for the full year 2025, although Q4 R&D expenses were $9.4 million, down from $12.4 million year-over-year, necessitating attention to how cost control impacts future innovation capabilities.
  • Market Opportunities and Customer Base: Cibus Inc. has secured seven rice customers, representing over $200 million in potential annual royalty revenue, while its partnership with the UK government highlights its leadership in agricultural innovation, potentially opening new revenue streams for the company.
  • Regulatory and Commercialization Progress: With the EU's political agreement on new genomic techniques legislation, Cibus Inc. has made significant advancements in gene editing technology, allowing for predictable trait development within 12 to 15 months, enhancing its appeal to seed companies and market access prospects.
seekingalpha
9.5
03-18seekingalpha
Cibus, Inc. Q4 2025 Earnings Call Highlights
  • Customer Relationship Evolution: Cibus has established partnerships with seven rice customers, representing over $200 million in potential annual royalty revenue, indicating strong global demand and commercialization progress that is expected to drive future revenue growth.
  • Financial Performance Improvement: As of December 31, 2025, the company reported cash and cash equivalents of $9.9 million, with a successful public offering raising $22.3 million in January 2026, reflecting positive advancements in financial management and operational efficiency.
  • Accelerated Technological Innovation: Cibus achieved a significant improvement in editing efficiency for rice, leveraging AI and machine learning to expedite product development, thereby enhancing market competitiveness and customer appeal.
  • Market Expansion Plans: The company aims for initial rice market entry in Latin America in 2027, U.S. expansion in 2028, and entry into India and Asia by 2030, demonstrating a clear path for its globalization strategy and long-term growth potential.
Wall Street analysts forecast CBUS stock price to rise
3 Analyst Rating
Wall Street analysts forecast CBUS stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
15.00
Averages
18.67
High
25.00
Current: 0.000
sliders
Low
15.00
Averages
18.67
High
25.00
Jefferies
Hold
maintain
$3
AI Analysis
2026-03-25
Reason
Jefferies
Price Target
$3
AI Analysis
2026-03-25
maintain
Hold
Reason
Jefferies raised the firm's price target on Cibus to $3 from $1.90 and keeps a Hold rating on the shares. With the capital raise in January and cost cutting measures, Cibus aims tot have ample cash for operating expenses and capex through at least 3Q26, the analyst tells investors in a research note. With EU genetic engineering regulations likely finalized in Q2, the firm expects a pickup in customer engagement in trait insertion, single-cell cloning, field trial efficiency solutions, and biofragrance production.
Canaccord
Austin Moeller
Buy
downgrade
$18
2025-05-12
Reason
Canaccord
Austin Moeller
Price Target
$18
2025-05-12
downgrade
Buy
Reason
Canaccord analyst Austin Moeller lowered the firm's price target on Cibus to $17.50 from $18 and keeps a Buy rating on the shares. The firm noted Cibus is not yet generating meaningful commercial revenues at this point in the company's lifecycle. However, through contract research on behalf of customers relating to collaborative agreements for products and traits, the company has consistently generated some quarterly revenue in advance of major trait commercializations. Cibus' nearest-term revenue-generation opportunity continues is its sustainable ingredients biofragrance product pipeline.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CBUS
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cibus Inc (CBUS.O) is -1.90, compared to its 5-year average forward P/E of -2.73. For a more detailed relative valuation and DCF analysis to assess Cibus Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.73
Current PE
-1.90
Overvalued PE
-0.91
Undervalued PE
-4.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.64
Current EV/EBITDA
-7.47
Overvalued EV/EBITDA
-1.13
Undervalued EV/EBITDA
-6.14

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
58.73
Current PS
11.63
Overvalued PS
143.40
Undervalued PS
-25.94

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

best option put tickers for rest of day
Intellectia · 1032 candidates
Volume: >= 200,000Price Change Pct: <= $-1.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceBelowMA20Is Optionable: True
Ticker
Name
Market Cap$
top bottom
CMBM logo
CMBM
Cambium Networks Corp
49.99M
TASK logo
TASK
Taskus Inc
949.08M
DERM logo
DERM
Journey Medical Corp
227.14M
CBUS logo
CBUS
Cibus Inc
198.59M
MLKN logo
MLKN
MillerKnoll Inc
1.32B
DYAI logo
DYAI
Dyadic International Inc
31.57M
what are pre market low cap movers
Intellectia · 48 candidates
Market Cap: 30.00M - 3.00BRegion: USPrice: $0.30 - $30.00List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $100.00
Ticker
Name
Market Cap$
top bottom
IPSC logo
IPSC
Century Therapeutics Inc
459.90M
CBUS logo
CBUS
Cibus Inc
213.22M
GEOS logo
GEOS
Geospace Technologies Corp
130.55M
OBE logo
OBE
Obsidian Energy Ltd
573.46M
CGNT logo
CGNT
Cognyte Software Ltd
634.70M
VET logo
VET
Vermilion Energy Inc
1.73B
stocks that are up 15 % in last month
Intellectia · 406 candidates
List Exchange: XNYS, XNAS, XASEMonth Price Change Pct: >= $15.00
Ticker
Name
Market Cap$
top bottom
ANL logo
ANL
Adlai Nortye Ltd
361.99M
NCI logo
NCI
Neo-Concept International Group Holdings Ltd
18.25M
LNKS logo
LNKS
Linkers Industries Ltd
16.66M
BATL logo
BATL
Battalion Oil Corp
67.97M
SGN logo
SGN
Signing Day Sports Inc
6.50M
MLEC logo
MLEC
Moolec Science SA
12.42M
top pick to buy today <$3
Intellectia · 34 candidates
Market Cap: >= 100.00MPrice: $0.50 - $3.00Moving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 60
Ticker
Name
Market Cap$
top bottom
ABOS logo
ABOS
Acumen Pharmaceuticals Inc
147.19M
CIG logo
CIG
Energy of Minas Gerais Co
6.16B
CRDL logo
CRDL
Cardiol Therapeutics Inc
112.24M
ROMA logo
ROMA
Roma Green Finance Ltd
119.13M
GORO logo
GORO
Gold Resource Corp
242.79M
ALTO logo
ALTO
Alto Ingredients Inc
199.16M
us stocks under 5$ marked to buy now
Intellectia · 85 candidates
Price: $0.50 - $5.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
CATX logo
CATX
Perspective Therapeutics Inc
281.74M
YCBD logo
YCBD
cbdMD Inc
10.92M
CNTX logo
CNTX
Context Therapeutics Inc
239.80M
ABOS logo
ABOS
Acumen Pharmaceuticals Inc
157.49M
ALLO logo
ALLO
Allogene Therapeutics Inc
413.50M
MNTK logo
MNTK
Montauk Renewables Inc
247.53M
most bullish ticker
Intellectia · 46 candidates
Analyst Consensus: Strong BuyTarget Price Upside Potential: MoreAbovePriceMoving Average Relationship: PriceAboveMA200Option Sentiments: BullishOne Week Rise Prob: >= 70
Ticker
Name
Market Cap$
top bottom
TARS logo
TARS
Tarsus Pharmaceuticals Inc
2.78B
DERM logo
DERM
Journey Medical Corp
276.86M
CYTK logo
CYTK
Cytokinetics Inc
7.93B
ABCL logo
ABCL
Abcellera Biologics Inc
1.19B
SVRA logo
SVRA
Savara Inc
1.16B
TSHA logo
TSHA
Taysha Gene Therapies Inc
1.29B

Whales Holding CBUS

B
BDT Capital Partners, LLC
Holding
CBUS
-2.16%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cibus Inc (CBUS) stock price today?

The current price of CBUS is 1.97 USD — it has increased 8.24

What is Cibus Inc (CBUS)'s business?

Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

What is the price predicton of CBUS Stock?

Wall Street analysts forecast CBUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CBUS is18.67 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cibus Inc (CBUS)'s revenue for the last quarter?

Cibus Inc revenue for the last quarter amounts to 1.06M USD, decreased -12.79

What is Cibus Inc (CBUS)'s earnings per share (EPS) for the last quarter?

Cibus Inc. EPS for the last quarter amounts to -0.59 USD, decreased -32.18

How many employees does Cibus Inc (CBUS). have?

Cibus Inc (CBUS) has 118 emplpoyees as of March 31 2026.

What is Cibus Inc (CBUS) market cap?

Today CBUS has the market capitalization of 138.63M USD.